AzTrials
AzTrials

Multiple MyelomaPhase 2ADVANCENCT04268498

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

A Phase 2 study testing Bortezomib, Dexamethasone and Lenalidomide in people with Multiple Myeloma, run by University of Miami at 7 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Multiple Myeloma
What is being tested?
Bortezomib, Dexamethasone and Lenalidomide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
310 participants
Where
7 sitesUnited States
Study dates
11 Feb 2020to 1 Feb 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Newly diagnosed patients with histologically confirmed Multiple Myeloma (MM) based on the IMWG diagnostic criteria and measurable disease within the past 4 weeks (or past 8 weeks if patient received pre-study MM therapy) based on one of the following:
  • Serum monoclonal protein ≥ 1.0 g/dL
  • Urine monoclonal protein ≥ 200 mg/24 hour
  • Involved serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal kappa/lambda ratio.
  • Evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following (Note: Myeloma defining event does not need to be based on repeat testing done at screening, if previous pathology, radiology, etc., confirm diagnosis of myeloma per IMWG)
  • Hypercalcemia: serum calcium >0.25 mmol/L (> 1 mg/dL) above upper limit of normal or ≥ 2.75 mmol/L (11 mg/dL)
Show all 22Show fewer
  • Anemia: hemoglobin value <10 g/dL or > 2 g/dL below lower limit of normal
  • Bone disease: ≥ 1 lytic lesions on skeletal X-ray, CT, or Positron Emission Tomography (PET)-C. For patients with 1 lytic lesion, bone marrow should demonstrate ≥10% clonal plasma cells
  • Clonal bone marrow plasma cell percentage ≥60%
  • Involved/un-involved serum free light chain ratio ≥100 and involved free light chain
  • ≥100 mg/L.
  • > 1 focal lesion on magnetic resonance imaging study (lesion must be >5 mm) in size
  • For patients with 1 lytic lesion, bone marrow should demonstrate ≥10% clonal plasma cells
  • Creatinine Clearance (CrCl) ≥ 60 ml/min. CrCl can be measured or estimated using Cockcroft-Gault method, Modification of Diet in Renal Disease (MDRD), or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae
  • Age ≥ 18 years at the time of signing the informed consent documentation. Age limit of ≤ 75 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Absolute neutrophil count (ANC) ≥ 1.0 K/microliter (uL), hemoglobin ≥ 8 g/dL, and platelet count ≥ 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator. Transfusions and growth factors are permissible.
  • Adequate hepatic function, with bilirubin < 1.5 x the pper Limit of Normal (ULN), and Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 3.0 x ULN.
  • All study participants must be able to tolerate one of the following thromboprophylactic strategies: aspirin, oral facto Xa inhibitors, low molecular weight heparin, warfarin (coumadin), or alternative anti-coagulant.
  • All study participants must be registered into the mandatory electronic REMS (eREMS) program and be willing and able to comply with the requirements of Risk Evaluation Management and Safety (REMS).
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
  • A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Who cannot join

  • Patients receiving >1 cycle of prior treatment or concurrent systemic treatment for multiple myeloma:
  • Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted
  • Bone targeting agents are permitted
  • Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted
  • Prior treatment with radiotherapy is permitted
  • Prior MM treatments, such as Immunomodulating Drugs (IMIDs) or non-MM drugs in clinical trials for smoldering myeloma is permitted with a washout period of 2 weeks from last dose. Smoldering patients previously treated with carfilzomib are excluded.
Show all 35Show fewer
  • Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 2 weeks from last dose (on a trial or outside a trial) are eligible (Note: Measurable disease is defined as one or more of the following: Serum monoclonal protein ≥ 1.0 g/dL, Urine monoclonal protein ≥ 200 mg/24 hour and/ or Involved serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal kappa/lambda ratio)
  • Prior or current exposure to any of the following:
  • To daratumumab or other anti- Cluster of Differentiation (CD) -38 therapies (unless a re-treatment study)
  • Exposure to an investigational drug (including investigational vaccine) or invasive investigational medical device for any indication within 4 weeks or 5 pharmacokinetic half-lives, whichever is longer.
  • Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma.
  • Patients with plasma cell leukemia
  • Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome (POEMS syndrome)
  • Patients with amyloidosis
  • Patients with known Chronic Obstructive Pulmonary Disorder (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD, and subjects must be excluded if FEV1 <50% of predicted normal.
  • Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study.
  • Pregnant or lactating females. Because there is a potential risk for AEs in nursing infants secondary to treatment of the mother with carfilzomib in combination with lenalidomide, pregnant or lactating females are excluded from study participation. These potential risks may also apply to other agents used in this study.
  • Uncontrolled hypertension (i.e., systolic blood pressure (BP) >160 mmHg, diastolic BP > 100 mmHg)
  • Uncontrolled diabetes (i.e., two independent glucose readings >200 mg/dL)
  • Active hepatitis B or C infection
  • Subject is:
  • Seropositive for human immunodeficiency virus (HIV)
  • Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core (HBc) antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (RT-PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.
  • Seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).
  • Patients with active Coronavirus Disease of 2019 (COVID-19) infection are not to be enrolled until 10 days have passed from the initial positive test, and the patient is symptom-free. COVID-19 vaccinations following national guidelines (i.e., CDC) are encouraged; however, the series should be completed prior to the first day of study treatment. If this is not possible, every effort should be made to administer vaccines at a time when patient is not scheduled to receive study treatment (e.g., "off-weeks").
  • Clinically significant cardiac disease, including:
  • Myocardial infarction within 6 months before randomization, or unstable or uncontrolled disease/condition related to or affection cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association (NYHA) Class III-IV) or a left ventricular ejection fraction of <40%.
  • Uncontrolled cardiac arrhythmia
  • Intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
  • Pulmonary hypertension
  • Has refractory gastrointestinal (GI) disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents
  • Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements
  • Significant neuropathy ≥ Grade 3 or Grade 2 neuropathy with pain at baseline
  • Contraindication to any concomitant medication, including antivirals or anticoagulation
  • Major surgery within 3 weeks prior to first dose

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

United States7 sites

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14203

  • MD Anderson Cancer Center

    Houston, Texas, 77030

  • University of Miami

    Miami, Florida, 33136

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

  • Huntsman Cancer Institue

    Salt Lake City, Utah, 84113

  • Stony Brook University

    Stony Brook, New York, 11794

  • Moffitt Cancer Center

    Tampa, Florida, 33612-9497

Other trials in United States

About this study

Official title: Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

Read the detailed description

Per protocol amendment version 4.0 (May 23, 2022), Arm A will be closed and no additional participants will be enrolled in this arm.

Being tested
Bortezomib, Dexamethasone, Lenalidomide, Acetaminophen, Diphenhydramine
Keywords
Daratumumab, Carfilzomib, Lenalidomide
Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BortezomibDrug

    1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.

  • DexamethasoneDrug

    20 mg or 40 mg per dose administered by mouth (PO) or IV.

    Participants randomized in Arm A:

    20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;

    Participants randomized in Arm B:

    Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle

    Participants randomized in Arm C:

    Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;

  • LenalidomideDrug

    Also called Revlimid

    10 or 25 mg/day capsules administered PO.

    Participants randomized in Arm A:

    25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;

    Participants randomized in Arm B:

    Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;

    Participants randomized in Arm C:

    Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;

    Maintenance Therapy:

    10 mg capsules on Days 1 through 21 on a 28 days cycle.

  • AcetaminophenDrug

    650 mg administered PO.

    Participants randomized to Arm C:

    Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15.

  • DiphenhydramineDrug

    25 mg administered via IV

    Participants randomized to Arm C:

    Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15.

  • MontelukastDrug

    10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.

  • CarfilzomibDrug

    20 mg or 56 mg/m2 per dose administered via IV.

    Participants randomized to Arm B:

    Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;

    Participants randomized to Arm C:

    Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle

  • DaratumumabDrug

    16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.

    Participants randomized to Arm C:

    Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle

  • Autologous Stem Cell Transplant (ASCT)Biological

    Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.

Study groups in NCT04268498
Study groupRoleWhat they receive
Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)ExperimentalParticipants in this group will receive Bortezomib, Lenalidomide and Dexamethasone on a 21 day treatment cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
Receives: Drug: Bortezomib; Drug: Dexamethasone; Drug: Lenalidomide; Biological: Autologous Stem Cell Transplant (ASCT)
Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)ExperimentalParticipants in this group will receive Carfilzomib, Lenalidomide and Dexamethasone on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
Receives: Drug: Dexamethasone; Drug: Lenalidomide; Drug: Carfilzomib; Biological: Autologous Stem Cell Transplant (ASCT)
Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)ExperimentalParticipants in this group will receive Carfilzomib, Lenalidomide, Dexamethasone with Daratumumab, Acetaminophen, Diphenhydramine and Montelukast on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
Receives: Drug: Dexamethasone; Drug: Lenalidomide; Drug: Acetaminophen; Drug: Diphenhydramine; Drug: Montelukast; Drug: Carfilzomib; Drug: Daratumumab; Biological: Autologous Stem Cell Transplant (ASCT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Minimal Residual Disease (MRD) Negativity

    MRD will be assessed by the MRD scale ranging from 10 (increased disease detection) to -5 (less to no disease detection) after 8 cycles of therapy.

    Measured: Up to 32 weeks

Secondary outcomes (7)

  1. Overall Survival

    Overall survival is defined as the time from date of randomization to death from any cause

    Measured: Up to 16 weeks

  2. Progression Free Survival (PFS)

    PFS is defined as time from date of randomization to time of progression or death, whichever occurs first.

    Measured: Up to 16 weeks

  3. Event Free Survival (EFS)

    EFS is defined as time from date of randomization to the time of 1) achieving a PR or less with the first four cycles of therapy, 2) transplant, 3) progression, or 4) death, whichever occurs first.

    Measured: Up to 16 weeks

  4. Rate of Response

    Rate of Response will be reported as the percentage of participants achieving a response of: a) Partial Response (PR) or better, b) Very Good Partial Response (VGPR) or better and c) Complete Response (CR) and Stringent Complete Response (sCR). Responses will be evaluated from participant serum, urine and bone marrow samples.

    Measured: Up to 3 years

  5. Rate of MRD Negativity as best response

    MRD will be evaluated from bone marrow samples.

    Measured: Up to 3 years

  6. Incidence of treatment related toxicity

    Toxicity will be evaluated by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Measured: Up to 9 months

  7. Minimal Residual Disease (MRD) Negativity

    MRD Negativity using bone marrow and blood samples

    Measured: Up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Feb 2020
  2. Study start11 Feb 2020
  3. Primary completion1 Feb 2027 (estimated)
  4. Study completion1 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
310 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04268498
Sponsor's protocol ID
20201316
Other IDs
2019-001645-41, 19-339, 2019
Acronym
ADVANCE
Status last verified
Mar 2026
First submitted
11 Feb 2020
Last updated
24 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Bortezomib, Dexamethasone and Lenalidomide in people with Multiple Myeloma, run by University of Miami at 7 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 22 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Minimal Residual Disease (MRD) Negativity (time frame: Up to 32 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04268498.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in